Beta Bionics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	100.25	65.12	12	0.18
Revenue Growth (YoY)	53.94%	442.93%	6601.12%	-
Cost of Revenue	44.71	29.24	5.69	-
Gross Profit	55.54	35.89	6.31	0.18
Selling, General & Admin	92.43	54.96	24.22	34.6
Research & Development	34.79	26.18	17.94	31.43
Total Operating Expenses	127.22	81.14	42.16	66.02
Operating Income	-71.68	-45.25	-35.85	-65.84
Interest Income	10.93	3.91	1.78	0.2
Interest Expense	-	-	-	-0.01
Other Non-Operating Income (Expense)	-12.45	-13.41	-10.03	0.91
Total Non-Operating Income (Expense)	-1.52	-9.51	-8.25	1.09
Pretax Income	-73.2	-54.76	-44.1	-64.75
Net Income	-73.2	-54.76	-44.1	-64.75
Net Income to Common	-73.2	-54.76	-44.1	-64.75
Shares Outstanding (Basic)	41	6	5	5
Shares Outstanding (Diluted)	41	6	5	5
Shares Change (YoY)	536.74%	20.01%	6.13%	-
EPS (Basic)	-1.81	-8.60	-8.31	-12.96
EPS (Diluted)	-1.81	-8.60	-8.31	-12.96
Free Cash Flow	-56.22	-51.67	-32.85	-60.98
Free Cash Flow Per Share	-1.39	-8.12	-6.19	-12.20
Gross Margin	55.40%	55.11%	52.59%	100.00%
Operating Margin	-71.50%	-69.48%	-298.87%	-36784.36%
Profit Margin	-73.02%	-84.08%	-367.64%	-36173.74%
FCF Margin	-56.08%	-79.34%	-273.84%	-34067.04%
EBITDA	-70.11	-44.1	-34.62	-64.5
EBITDA Margin	-69.93%	-67.72%	-288.65%	-36032.96%
EBIT	-71.68	-45.25	-35.85	-65.84
EBIT Margin	-71.50%	-69.48%	-298.87%	-36784.36%

Updated Feb 17, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q